Analytical Data
-
Gene name
KYNU
- Application
-
Alternative Names
KYNU；Kynureninase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16719
-
Expression Region
1-307aa
-
AA Sequence
MEPSSLELPADTVQRIAAELKCHPTDERVALHLDEEDKLRHFRECFYIPKIQDLPPVDLSLVNKDENAIYFLGNSLGLQPKMVKTYLEEELDKWAKIAAYGHEVGKRPWITGDESIVGLMKDIVGANEKEIALMNALTVNLHLLMLSFFKPTPKRYKILLEAKAFPSDHYAIESQLQLHGLNIEESMRMIKPREGEETLRIEDILEVIEKEGDSIAVILFSGVHFYTGQHFNIPAITKAGQAKGCYVGFDLAHAVGNVELYLHDWGVDFACWCSYKYLNAGAGGIAGAFIHEKHAHTIKPARSEFFN
-
Molecular Weight
61.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KYNU, or Kynureninase, is an enzyme involved in the kynurenine pathway, a crucial metabolic route that links tryptophan metabolism to the production of various bioactive metabolites, including kynurenine and quinolinic acid. Research into KYNU is gaining traction due to its significant role in neurobiology and immunology, as the metabolites produced in this pathway are implicated in numerous physiological and pathological processes, including neurodegenerative diseases, depression, and immune responses. Dysregulation of KYNU activity has been associated with various disorders, making it a potential therapeutic target. The recombinant expression of KYNU allows researchers to produce the enzyme in a controlled laboratory setting, facilitating detailed studies on its structure, function, and regulatory mechanisms. This can enhance our understanding of its role in health and disease and aid in the development of novel therapeutic strategies aimed at modulating the kynurenine pathway. The ability to produce well-characterized KYNU also paves the way for high-throughput screening of potential inhibitors or activators, which could lead to innovative treatments for conditions linked to imbalances in this metabolic pathway.
